Newswise — CHICAGO – The American Society of Anesthesiologists (ASA) today announced Heron Therapeutics, Inc., a developer of novel, pharmaceutical treatments to reduce postsurgical pain and for patients with cancer, has joined ASA’s Industry Supporter Program to support the Society’s more than 53,000 physician anesthesiologists members and improve patient care.

“Establishing a partnership with Heron is an exciting new opportunity for ASA and its members,” said ASA President Linda J. Mason, M.D., FASA. “As physician anesthesiologists and experts in pain management, we share a common goal with Heron and that is their steadfast commitment to improving postsurgical pain while reducing the need for opioids.”

As an Industry Supporter, Heron is helping to improve the lives of patients through a strong, mutually beneficial relationship within the anesthesiology community, strengthen collaboration between physician anesthesiologists and industry, and add to the value the Society provides to patients and the public, while providing invaluable year-round support of ASA initiatives and priorities in regards to patient safety and quality of care.

Through the program, Heron will have unique opportunities to inform strategic dialogue with leaders in anesthesiology from around the world and during major ASA events including the ANESTHESIOLOGY® annual meeting, PRACTICE MANAGEMENT™ conference and Anesthesia Quality Meeting™. Their participation will be instrumental to educational, quality and regulatory affairs initiatives for ASA members, as well as initiatives supporting the Perioperative Surgical Home model of care.

“Heron is pleased to support ASA and we look forward to collaborating in our efforts to improve patient care, especially postsurgical pain management,” said Heron Therapeutics President and Chief Executive Officer Barry Quart, Pharm.D. “Both organizations have a shared goal to optimize innovative non-opioid postoperative pain management options that can reduce the amount of opioids used after surgery and, ultimately, the number of unused pills in our homes and communities.”

Launched in 2010, ASA’s Industry Supporter Program is limited to 10 organizations. Participation is intended for companies who want to stand apart by showcasing high-level commitment to the education of physician anesthesiologists, the anesthesia care team and advancement of the specialty.



Heron Therapeutics, Inc., is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. For more information, visit



Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 53,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at To learn more about the role physician anesthesiologists play in ensuring patient safety, visit Like ASA on Facebook and follow ASALifeline on Twitter.


# # #